CN111065927B - 作为危重患者的治疗监测标记物的pro-adm - Google Patents

作为危重患者的治疗监测标记物的pro-adm Download PDF

Info

Publication number
CN111065927B
CN111065927B CN201880059136.6A CN201880059136A CN111065927B CN 111065927 B CN111065927 B CN 111065927B CN 201880059136 A CN201880059136 A CN 201880059136A CN 111065927 B CN111065927 B CN 111065927B
Authority
CN
China
Prior art keywords
sample
level
fragment
proadm
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880059136.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111065927A (zh
Inventor
D·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of CN111065927A publication Critical patent/CN111065927A/zh
Application granted granted Critical
Publication of CN111065927B publication Critical patent/CN111065927B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880059136.6A 2017-09-13 2018-09-13 作为危重患者的治疗监测标记物的pro-adm Active CN111065927B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190912.0 2017-09-13
EP17190912 2017-09-13
PCT/EP2018/074722 WO2019053115A1 (en) 2017-09-13 2018-09-13 USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS

Publications (2)

Publication Number Publication Date
CN111065927A CN111065927A (zh) 2020-04-24
CN111065927B true CN111065927B (zh) 2023-10-17

Family

ID=59887050

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880059136.6A Active CN111065927B (zh) 2017-09-13 2018-09-13 作为危重患者的治疗监测标记物的pro-adm
CN201880059366.2A Active CN111094986B (zh) 2017-09-13 2018-09-13 基于肾上腺髓质素前体的指导流体治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880059366.2A Active CN111094986B (zh) 2017-09-13 2018-09-13 基于肾上腺髓质素前体的指导流体治疗的方法

Country Status (7)

Country Link
US (3) US20200300864A1 (https=)
EP (2) EP3682245A1 (https=)
JP (4) JP7329503B2 (https=)
CN (2) CN111065927B (https=)
BR (1) BR112020004138A2 (https=)
CA (1) CA3075440A1 (https=)
WO (2) WO2019053116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026013199A1 (en) 2024-07-12 2026-01-15 Cezanne S.A.S. Clinical immunoassay with early signal measurement
CN118976116B (zh) * 2024-10-22 2025-01-24 四川大学华西医院 琥珀酰明胶在制备腹膜透析液中的用途以及一种含琥珀酰明胶、枸橼酸钠的腹膜透析液

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012019A2 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur steuerung der therapie von patienten mit herzinsuffizienz anhand der in vitro bestimmung von schwellenwerten von vasoaktiven peptiden
EP2131200A1 (en) * 2008-06-04 2009-12-09 BRAHMS Aktiengesellschaft A marker for graft failure and mortality
CN102428368A (zh) * 2009-05-05 2012-04-25 B.R.A.H.M.S有限公司 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
CN105102985A (zh) * 2013-03-20 2015-11-25 斯弗因高泰克有限公司 用于指导血压下降疗法的肾上腺髓质素
CA3006390A1 (en) * 2015-11-27 2017-06-01 B.R.A.H.M.S Gmbh Mr-proadm as marker for the extracellular volume status of a subject

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
DE69602756T2 (de) 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
KR100425525B1 (ko) 2000-11-21 2004-03-30 재단법인서울대학교산학협력재단 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
US6864237B2 (en) * 2002-05-17 2005-03-08 Ping Wang Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US8298774B2 (en) 2007-03-12 2012-10-30 Biomedica Medizinprodukte Gmbh & Co Kg Diagnosis of septic complications
PL2185937T5 (pl) 2007-09-07 2014-12-31 Univ Zuerich Sposób wykrywania posocznicy u ludzi
ES2486268T3 (es) 2007-11-16 2014-08-18 Biocartis Nv Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos
JP5989965B2 (ja) * 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
JP5702371B2 (ja) * 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
EP2438447B1 (en) 2009-06-05 2015-02-18 B.R.A.H.M.S GmbH Detection of bacterial infections in subjects suffering from dyspnea.
US8383332B2 (en) 2009-10-13 2013-02-26 B.R.A.H.M.S. Gmbh Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
EP2545379B1 (en) 2010-03-08 2015-09-30 B.R.A.H.M.S GmbH Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
SG11201402362VA (en) * 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
CA2856150A1 (en) * 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
DK2780717T3 (en) * 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
US9597730B2 (en) * 2013-04-19 2017-03-21 United Technologies Corporation Build plate and apparatus for additive manufacturing
EP4231018A3 (en) 2016-07-08 2023-11-15 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure
CA3033094A1 (en) 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012019A2 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur steuerung der therapie von patienten mit herzinsuffizienz anhand der in vitro bestimmung von schwellenwerten von vasoaktiven peptiden
EP2131200A1 (en) * 2008-06-04 2009-12-09 BRAHMS Aktiengesellschaft A marker for graft failure and mortality
CN102428368A (zh) * 2009-05-05 2012-04-25 B.R.A.H.M.S有限公司 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
CN105102985A (zh) * 2013-03-20 2015-11-25 斯弗因高泰克有限公司 用于指导血压下降疗法的肾上腺髓质素
CA3006390A1 (en) * 2015-11-27 2017-06-01 B.R.A.H.M.S Gmbh Mr-proadm as marker for the extracellular volume status of a subject

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients;Jochen Gille 等;《Journal of Burn Care & Research》;20170831;第1-9页 *
Pro-adrenomedullin as a Novel Biomarker for Predicting Infections and Response to Antimicrobials in Febrile Patients With Hematologic Malignancies;Munirah Al Shuaibi 等;《Clinical Infectious Diseases》;20130103;第56卷(第7期);第943-950页 *
Time-dependent Cox regression: Serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection;Oliver Hartmann 等;《International Journal of Cardiology》;20120924;第161卷;第166-173页 *

Also Published As

Publication number Publication date
BR112020004138A2 (pt) 2020-09-08
RU2020111719A3 (https=) 2021-12-17
JP2020533604A (ja) 2020-11-19
US20200300864A1 (en) 2020-09-24
US20250189539A1 (en) 2025-06-12
EP3682246A1 (en) 2020-07-22
CN111094986B (zh) 2023-11-10
WO2019053116A1 (en) 2019-03-21
JP7366007B2 (ja) 2023-10-20
US20200271667A1 (en) 2020-08-27
EP3682245A1 (en) 2020-07-22
CN111094986A (zh) 2020-05-01
WO2019053116A8 (en) 2022-03-17
JP2023181226A (ja) 2023-12-21
WO2019053115A1 (en) 2019-03-21
JP7329503B2 (ja) 2023-08-18
JP7544879B2 (ja) 2024-09-03
CN111065927A (zh) 2020-04-24
US12517138B2 (en) 2026-01-06
RU2020111719A (ru) 2021-10-13
JP2023041741A (ja) 2023-03-24
JP2020537117A (ja) 2020-12-17
CA3075440A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
US20220187313A1 (en) Diagnosis or Prognosis of Postsurgical Adverse Events
CN111630381B (zh) 基于pro-adm的抗生素疗法指导
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
US20240393352A1 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment
HK40030378B (zh) 基於pro-adm的抗生素疗法指导

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant